News Releases

December 10, 2023
Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported responder in dose range three MP0533 monotherapy continues to demonstrate an acceptable safety
November 2, 2023
MP0533 shows acceptable safety profile in first three dose cohorts (5 patients total, data cut-off July 20); reported adverse reactions are of Grade 1/2 and no dose-limiting toxicity observed to date Emerging evidence of antitumor activity observed in dose cohort three, with one responder noted
May 25, 2023
MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W regimens, including the highest dose tested, 10mg/kg (Q3W) Present data support planning of future combination
Displaying 1 - 10 of 36
* These releases may contain price sensitive information